NOAHS-ARC: No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer
Study Details
Study Description
Brief Summary
This study is designed to explore the hypothesis that in patients with a Locally advanced rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) strategy based on short course radiotherapy (5x5Gy) followed by neoadjuvant consolidation chemotherapy is associated with a higher rate of pathological clinical response and sustained (>1year) complete clinical response when compared to an historical cohort treated with long course chemoradiation therapy (CRT), total mesorectal excision (TME) and adjuvant chemotherapy (ACT).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Non-operative management with a Watch and Wait (W&W) strategy has been advocated for selected patients with a locally advanced rectal cancer (LARC) and a complete clinical response (cCR) after neoajuvant (NA) treatment.
In this context, total neoadjuvant therapy (TNT), i.e the use of radiotherapy and full dose of post-operative chemotherapy as part of NA treatment, has emerged as a strategy to enhance treatment response.
Currently, TNT has reported higher rates of pCR and organ preservation when compared to current standard of care. However, the best TNT strategy is still unknown. We therefore hypothesize that in LARC patients, the use of a TNT strategy based on short course RT followed by consolidation chemotherapy is associated with a higher rate of pCR and sustained (>1year) cCR when compared to an historic cohort.
The main aim of the present proposal is to assess the effects of a standardized TNT model in LARC patients as a strategy for enhanced pCR/sustained cCR. For this purpose, we propose the following experimental model: In primary Aim 1 we will study if the effects of a TNT strategy over patients with a LARC enhance the rate of pCR/sustained cCR by (1) evaluating the compliance and toxicity of a TNT strategy as a proof of concept of its applicability, (2) assessing the rate of cCR at the end of TNT and (3) assessing the rate of pCR in the surgically managed subgroup and sustained cCR (>1year) in the W&W subgroup. Additionally, in primary Aim 2, we will determine if patients with a W&W strategy have better functional outcomes and quality of life (QoL) than patients treated with TME after TNT by (1) using validated questionnaires for the evaluation of bowel, sexual and urinary function for W&W and TME patients and (2) by evaluating the QoL using a widely-used standardized questionnaire.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Short Course Radiotherapy and Consolidation Chemotherapy This arm will receive short course radiotherapy (5x5 Gy) during 1 week. Between 7 to 14 days after radiotherapy, patient will receive 9 cycles of FOLFOX. CapeOX may be given as alternative for FOLFOX. |
Drug: Oxaliplatin
Consolidation Chemotherapy
Other Names:
Drug: 5-Fluoracil
Consolidation Chemotherapy
Other Names:
Drug: Leucovorin
Consolidation Chemotherapy
Other Names:
Drug: Capecitabine
Consolidation Chemotherapy
Other Names:
Radiation: 5x5 Gy
Neoadjuvant Radiotherapy
Behavioral: Quality of Life Questionnaires
Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)
Procedure: DRE/ Endoscopy
Flexible Sigmoidoscopy and Digital Rectal Exam
|
Outcome Measures
Primary Outcome Measures
- Rate of pathological and sustained clinical response [3 years]
Combined number of patients with pathological response in the surgical specimen and patients in a Watch and Wait protocol with a sustained clinical response longer than a year.
- Quality of Life and Funcional Outcomes [3 years]
Standardized evaluation using validated questionnaires comparing patients undergoing TME versus WW patients in the cohort
Secondary Outcome Measures
- Adverse events [3 years]
Adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed diagnosis of adenocarcinoma of the rectum
-
Clinical Stage II (T3-4, N-) or Stage III (any T, N+) based on Magnetic Resonance Imaging (MRI)
-
Tumors < 7cm from anal verge (palpable)
-
No prior history of rectal cancer
Exclusion Criteria
-
Patients with tumors >7cm from anal verge
-
ECOG >1,
-
Contraindication for chemotherapy: Hemoglobin <8, White Blood Count <4000, Platelets <100,000, Creatinine Clearance <50ml/min, Total Bilirubin <5mg/dl,
-
Stage IV at diagnosis
-
Coronary artery disease, either no treated or recent acute coronary syndrome in the last 12 months.
-
Congestive heart failure
-
Peripheral neuropathy
-
Previous pelvic radiotherapy
-
Prior rectal cancer treatment
-
Pregnancy or nursery
-
Any contraindications to MRI (e.g. patients with pacemakers)
-
Indication of pelvic exenteration
-
Impossibility to consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Complejo Asistencial Doctor Sótero del Rio | Santiago | RM | Chile | |
| 2 | Hospital La Florida | Santiago | RM | Chile | |
| 3 | Hospital Padre Hurtado | Santiago | RM | Chile |
Sponsors and Collaborators
- Servicio de Salud Metropolitano Sur Oriente
Investigators
- Principal Investigator: Felipe F Quezada-Diaz, MD, Complejo Asistencial Doctor Sótero del Rio
- Principal Investigator: Nicole M Caire, MD, Complejo Asistencial Doctor Sótero Del Río
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FONDECYT 11201291